Seven Leading AI Drug Developers
Analysis of 32 Clinical Trials

AI Drugs Accelerate from Phase 2 Trials
KRW 164 Trillion in Annual Economic Value
Up to 40% Reduction in R&D Costs

Editor's NoteArtificial Intelligence (AI) is fundamentally transforming the pharmaceutical and biotechnology markets. Nvidia’s partnership with global big pharma Eli Lilly to invest USD 1 billion (approximately KRW 1.499 trillion) in AI-driven drug development marks a paradigm shift in the pharmaceutical and biotech industries. The territory of AI, which was once limited to discovering candidate compounds, now extends across the entire drug development cycle, including sophisticated clinical trial design, optimal patient cohort selection, and real-time manufacturing process control, fundamentally restructuring the industry's economics. AI has reduced the time required to identify candidate compounds from an average of 3–4 years to as little as one year. Leveraging three-dimensional understanding of target proteins and enhanced toxicity prediction accuracy, AI has raised the clinical Phase 1 success rate—traditionally between 40% and 65%—to 80–90%. The efficiency of AI in mitigating the astronomical sunk costs associated with early-stage failures is the only breakthrough for companies facing the so-called "valley of death" in drug development. Through the special series "K-Bio at the AI Crossroads," The Asia Business Daily examines the rapidly evolving landscape of global new drug development in 2026, shaped by this race for speed, and explores the path to survival and growth for Korea’s bio industry.
[K-Bio at the AI Crossroads][Column ①] AI Drugs: Not Just a Wave, But a Tide View original image

Clinical trials led by global AI-driven drug development companies have surpassed 30 cases, rapidly breaking through the physical barriers to drug commercialization. The speed at which AI drug development companies identify drug candidates and advance to clinical trials is expected to accelerate further as AI becomes more sophisticated. In particular, this year marks the beginning of commercialization, as efficacy data from late-stage clinical trials (Phase 3) of AI-discovered pipelines are being announced in earnest, making the birth of the world's first "AI drug" increasingly likely.


AI-Driven Drugs Accelerate Beyond Phase 2


On March 18, The Asia Business Daily tracked the pipelines of seven major global AI drug developers—Generate Biomedicines, Insilico Medicine, Recursion Pharmaceuticals, Relay Therapeutics, Absci, BenevolentAI, and Iambic Therapeutics—using the clinical trial database of the National Library of Medicine (NLM) under the U.S. National Institutes of Health (NIH). The results showed that these companies are leading a total of 32 clinical trials, with an average duration of 25 months (about 2.1 years) to reach the "primary completion date," when the main evaluation endpoints are achieved.


The number of new clinical trials launched soared from just two in 2021 to eight in 2023, seven in 2024, and another eight last year, depicting a clear upward curve. In clinical trials, the primary completion date refers to the point when essential data from the last patient has been collected to confirm that the drug has met its primary efficacy and safety objectives. Based on this, the core data known as "top-line results"—which determine the success or failure of the trial—are derived.


Timelines by clinical phase have changed even more dramatically. Traditional drug development methods typically require as much as 1–1.5 years for Phase 1 data collection, 2–3 years for Phase 2, and 3–4 years for Phase 3. The average duration of Phase 1 clinical trials for AI-driven drugs, where safety must be verified, was found to be 25.6 months. This is actually longer than traditional drug development, as the biological observation period for metabolism in the body cannot be skipped, and recent Phase 1 trials often employ a "cohort expansion" design to verify not only safety but also initial efficacy, thereby extending the period to over two years.

[K-Bio at the AI Crossroads][Column ①] AI Drugs: Not Just a Wave, But a Tide View original image

The true strength of AI becomes clear from Phase 2, where patient recruitment and efficacy verification ramp up. Traditional pharmaceutical companies often struggle with Phase 2 trials, taking 24 to over 36 months as they randomly select patients without large-scale clinical data simulations. In contrast, AI pipelines dramatically reduce Phase 2 duration to an average of 19.5 months by precisely identifying patients with optimal biomarkers for efficacy. Furthermore, even for large-scale Phase 3 trials—which typically require registering many patients and long-term follow-up, taking an average of 36–48 months or more—AI-powered clinical design optimization has reduced both patient recruitment time and trial failure rates, bringing the average time to meet primary endpoints down to 32.1 months.


The differences become even more pronounced when analyzing major target diseases. AI-driven drug developers are working on a wide range of diseases, from cancer and respiratory illnesses to rare neurological disorders where patient recruitment is extremely challenging. For 14 clinical trials targeting advanced and metastatic solid tumors such as breast cancer and non-small cell lung cancer—the main focus for companies like Relay Therapeutics, Iambic Therapeutics, and Recursion Pharmaceuticals—the average time to the primary completion date was just 21.8 months (about 1.8 years). This is more than a year faster than the usual three years or more required for late-stage oncology trials using traditional methods.


KRW 164 Trillion in Annual Economic Value... Up to 40% R&D Cost Reduction


Thanks to this efficient clinical trial design optimization, even late-stage clinical entry—often the most difficult to achieve—is becoming increasingly common. Relay Therapeutics has reached Phase 3 with its targeted anticancer pipeline, and Generate Biomedicines, a leader in generative AI-based protein design, has recently advanced two pipelines—including a severe asthma treatment candidate (GB-0895)—to Phase 3 clinical trials. In addition, Insilico Medicine’s idiopathic pulmonary fibrosis treatment "ISM001-055," known as the world’s first AI-developed drug, is progressing smoothly through Phase 2/3 trials.


[K-Bio at the AI Crossroads][Column ①] AI Drugs: Not Just a Wave, But a Tide View original image

In the bio industry, time and sunk costs translate directly into money. Steve Sugino, Vice President of Bristol Myers Squibb (BMS) for the Asia-Pacific region, told this reporter last year that "even a 5–6 percentage point increase in the technical success rate at the preclinical and Phase 1 stages through AI adoption improves both the quantity and quality of the entire pipeline while significantly reducing development costs and timelines. Ultimately, this can double the overall productivity of the industry," he said.


Albert Bourla, CEO of Pfizer, shared concrete cost reduction results at this year’s JP Morgan Healthcare Conference, the world’s largest bio investment event. He said, "Through the adoption of AI, we achieved cost savings of USD 5.6 billion (about KRW 8.246 trillion) just last year," and added, "This year, we will especially expand AI integration into manufacturing processes to further maximize enterprise-wide operational efficiency."



According to reports such as "The economic potential of generative AI (2023)" by McKinsey Global Institute (MGI), AI is identified as a key driver that can dramatically reduce the more than 10 years and over KRW 1 trillion typically required for new drug development by 20–40%. Market research firm MarketsandMarkets forecasts that the size of the global AI drug development market will grow from USD 1.86 billion (about KRW 2.7351 trillion) in 2024 at a compound annual growth rate of 29.9%, reaching USD 6.89 billion (about KRW 10.1317 trillion) by 2029.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing